Minejima Emi, Bensman Joyce, She Rosemary C, Mack Wendy J, Tuan Tran Martin, Ny Pamela, Lou Mimi, Yamaki Jason, Nieberg Paul, Ho Joyce, Wong-Beringer Annie
1Department of Pharmacy, University of Southern California, Los Angeles, CA. 2Department of Pathology, Keck School of Medicine, Los Angeles, CA. 3Department of Preventative Medicine, Keck School of Medicine, Los Angeles, CA. 4Department of Pharmacy, Huntington Hospital, Pasadena, CA. 5Department of Medicine, Huntington Hospital, Pasadena, CA.
Crit Care Med. 2016 Apr;44(4):671-9. doi: 10.1097/CCM.0000000000001465.
The contribution of individual immune response to Staphylococcus aureus bacteremia on outcome has not been well studied. The objective was to relate the host cytokine response to outcome of Staphylococcus aureus bacteremia.
Prospective observational study.
Three U.S. university-affiliated medical centers.
Adult patients infected with Staphylococcus aureus bacteremia hospitalized between July 2012 and August 2014.
Blood specimens were obtained at Staphylococcus aureus bacteremia onset and 72 hours after therapy initiation. Levels of tissue necrosis factor, interleukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorbent assay at each time point and compared between those with persistent bacteremia (≥ 4 d) and resolving bacteremia. Primary outcome was persistent bacteremia after 4 days of effective therapy. Secondary outcomes were 30-day mortality and 30-day recurrence.
A total of 196 patients were included (mean age, 59 yr); of them, 33% had methicillin-resistant Staphylococcus aureus bacteremia. Forty-seven percent of the methicillin-resistant Staphylococcus aureus strains were staphylococcal cassette chromosome mec IV. Persistent bacteremia occurred in 24% of patients (47/196); they were more likely to die than resolving bacteremia group (28% vs 5%; p < 0.001). Compared with resolving bacteremia group, persistent bacteremia patients had higher initial median levels of tissue necrosis factor (44.73 vs 21.68 pg/mL; p < 0.001), interleukin-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001). Despite 72 hours of treatment, levels remained higher for the persistent bacteremia group than for the resolving bacteremia group (tissue necrosis factor: 26.95 vs 18.38 pg/mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001). Interleukin-17A levels were similar between groups at both time points. After controlling for confounding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours most significantly predicted persistence (odds ratio, 2.98; 95% CI, 1.39-6.39; p = 0.005) and mortality (odds ratio, 9.87; 95% CI, 2.64-36.91; p < 0.001) at values more than 1.00 and more than 2.56, respectively.
Sustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours suggests a dysregulated immune response and may be used to guide management to improve outcomes.
个体免疫反应对金黄色葡萄球菌菌血症结局的影响尚未得到充分研究。本研究旨在探讨宿主细胞因子反应与金黄色葡萄球菌菌血症结局之间的关系。
前瞻性观察性研究。
美国三家大学附属医院。
2012年7月至2014年8月期间因金黄色葡萄球菌菌血症住院的成年患者。
在金黄色葡萄球菌菌血症发作时及治疗开始后72小时采集血标本。采用酶联免疫吸附测定法在每个时间点测量组织坏死因子、白细胞介素-6、白细胞介素-8、白细胞介素-17A和白细胞介素-10的水平,并比较持续菌血症(≥4天)患者和菌血症缓解患者之间的差异。主要结局为有效治疗4天后的持续菌血症。次要结局为30天死亡率和30天复发率。
共纳入196例患者(平均年龄59岁);其中,33%为耐甲氧西林金黄色葡萄球菌菌血症。47%的耐甲氧西林金黄色葡萄球菌菌株为葡萄球菌盒式染色体mec IV型。24%的患者(47/196)发生持续菌血症;与菌血症缓解组相比,他们死亡的可能性更大(28%对5%;p<0.001)。与菌血症缓解组相比,持续菌血症患者初始时组织坏死因子(44.73对21.68 pg/mL;p<0.001)、白细胞介素-8(124.76对47.48 pg/mL;p=0.028)和白细胞介素-10(104.31对29.72 pg/mL;p<0.001)的中位数水平更高。尽管经过72小时治疗,持续菌血症组的水平仍高于菌血症缓解组(组织坏死因子:26.95对18.38 pg/mL,p=0.02;白细胞介素-8:70.75对27.86 pg/mL,p=0.002;白细胞介素-6:67.50对21.81 pg/mL,p=0.005;白细胞介素-10:30.98对12.60 pg/mL,p<0.001)。两个时间点两组间白细胞介素-17A水平相似。通过多变量分析控制混杂变量后,72小时时白细胞介素-10/组织坏死因子比值最能显著预测持续菌血症(比值比,2.98;95%可信区间,1.39-6.39;p=0.005)和死亡率(比值比,9.87;95%可信区间,2.64-36.91;p<0.001),当比值分别大于1.00和大于2.56时。
72小时时白细胞介素-10/组织坏死因子比值持续升高提示免疫反应失调,可用于指导治疗以改善结局。